ETView Medical, Ltd. Announces State Food and Drug Administration (SFDA, China) Clearance of a Pre-marketing Notification

  ETView Medical, Ltd. Announces State Food and Drug Administration (SFDA,
  China) Clearance of a Pre-marketing Notification Application for the
  VivaSight-SL Line of Innovative Airway Devices

Business Wire

TEL AVIV, Israel -- March 18, 2013

ETView (TASE: ETVW) today announced that the company has received clearance of
a Pre-Marketing Notification Application with the State Food and Drug
Administration (SFDA, China). The Company expects to enter the Chinese market
with the VivaSight-SL immediately. VivaSight-SL will be exclusively
distributed throughout China by the China National Pharmaceutical Group
Corporation, SINOPHARM. Additional pre-market regulatory clearances world-wide
are anticipated during 2013.

About the VivaSight-SL

VivaSight™-SL is a single-use disposable single lumen ventilation tube with an
integrated continuous high resolution video imaging system for use in lung
isolation procedures. VivaSight™-SL has been cleared for commercial
distribution by the US FDA and has received CE pre-market clearance. Lung
isolation is employed to provide one-lung ventilation in patients undergoing
thoracic, cardiac, vascular or esophageal surgeries.^1 It is estimated that
over 1.9 million lung isolation procedures are conducted world-wide
annually^2, accounting for over $250MM in single-use medical disposables^3.

"We are excited to have reached this milestone," stated Bill Edelman, CEO. He
continued, "VivaSight-SL is now available to the Chinese thoracic surgical
community following SFDA clearance of our pre-market application. We
anticipate significant clinical interest for this innovative technology in the
markets where VivaSight-SL is cleared for commercial distribution. With our
line of VivaSight™ products available in the US, South America, Europe and now
China, ETView offers a complete airway management solution for 100% of
lung-isolation surgeries. We look forward to additional regulatory clearances
world-wide which will expand the market for our VivaSight™ portfolio."

See www.etview.com for addition press announcements.

About ETView

ETView Medical Ltd. (TASE: ETVW) has successfully combined airway management
with continuous direct airway visualization for medical professionals.
ETView's patented VivaSight™ airway management portfolio consists of
single-use disposable medical devices, representing either single or double
lumen ventilation tubes with an integrated continuous high resolution airway
imaging system. VivaSight™-SL and VivaSight™-DL are currently sold in Europe,
Israel, and the US to overcome current limitations and associated adverse
surgical events during lung isolation surgeries.^4

About SINOPHARM

China National Pharmaceutical Group Corporation, SINOPHARM, is the largest
pharmaceutical and healthcare group under State-Owned Assets Supervision and
Administration Commission of the State Council (SASAC) in China. The group has
22 wholly-owned subsidiaries and holding companies, one H-share listed
company, Sinopharm Group Co., Ltd., and three A-share listed companies,
Beijing Tiantan Biological Products Corporation Limited (BTBP), China National
Medicines Co., Ltd. (CNCM) and Shenzhen Accord Pharmaceutical Co., Ltd.. In
2009, the group’s sale revenue had reached 65 billion Yuan. Among the 129
enterprises under SASAC, SINOPHARM is ranked 50th and 38th in terms of sales
revenue and total profit respectively.

Forward Looking Statement

The Company estimationsin thispress release,including those estimations
regardingthe Company's predicted scope of business,
constituteforward-looking statements, as such term is defined under the
Israeli Securities Law (5728-1968), and there is no certainty that such
estimations shall materialize.The Company's estimations are based on business
assumptions, prior experience, and professional data. Due to various factors,
foreseen and unforeseen, including, but not limited to,changes in market
trends, competition, global or local economic conditions, andamendments of
regulation, such estimations may not materialize in whole or in part, or
materialize in a substantially differentmanner than anticipated by the
Company.

^1 Principles and Practices of Anesthesia for Thoracic Surgery P. Singer (ed.)
2011
^2 National Health Statistics Reports Number 29, October 26, 2010
^3 Company estimates on file
^4 Anesthesiology, 2006;105:471-477

Contact:

ETView Medical, Ltd
Bill Edelman, CEO
bill.edelman@etview.com
Worldwide: +1 567 248 4821
In Israel: +972 72 260 7060
www.etview.com
 
Press spacebar to pause and continue. Press esc to stop.